

PATENT  
Attorney Docket No: AND-1001-DIV2  
AMENDMENTS

RECEIVED  
CENTRAL FAX CENTER  
MAR 13 2009

Amendments to the claims:

This listing of claims will replace all previous versions, and listing of claims in the application.

1-14 (Cancelled)

15. (Previously presented) A column device according to claim 19 wherein said artificial antigen presenting cell comprises:

- a) a liposome comprising a lipid bilayer comprised of neutral phospholipids and cholesterol;
- b) at least one GM-1 ganglioside molecule disposed in the lipid bilayer;
- c) a cholera toxin B subunit bound to a GM-1 ganglioside molecule ;
- d) an MHC:antigen component wherein said MHC:antigen component is bound to the cholera toxin B subunit; and
- e) an accessory molecule that can stabilize an interaction between a T cell receptor and the antigen-loaded MHC component.

16. (Previously presented) A column device of claim 19 wherein said multiplicity of compartments are positioned in relation to one another in series, said compartments having a channel interconnecting adjacent compartments, said channels further having a means to isolate said compartments from one another, said compartments further having at least one entrance and at least one exit ports for receiving or expelling, respectively, a flowable medium, said ports further having a means to close said ports to impede said flowable medium.

17. (Original) A column device according to claim 16 wherein at least one of said compartments comprises solid supports capable of binding and immobilizing an artificial

## PATENT

Attorney Docket No: AND-1001-DIV2

APC or alternatively capable of binding directly MHC:antigen:functional molecule complexes.

18. (Original) A column device according to claim 17 wherein binding and immobilizing of an artificial APC is by a solid support capable of binding an irrelevant molecule.

19. (Presently Amended) A column device comprising:

- a) a chamber comprising a multiplicity of compartments;
- b) in at least one of said compartments a solid support capable of binding [either an MHC antigen:functional molecule complex or] an artificial antigen presenting cell comprising at least one GM ganglioside molecule and at least one choler toxin B subunit; and
- c) in at least one of said compartments either an MHC antigen:functional molecule complex or an artificial antigen presenting cell.

20. (Previously presented) A column device according to claim 15 wherein said accessory molecule is selected from the group consisting of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), CD49d/29(VLA-4) and antibodies or fragments thereof to ligands for each of LFA-1, CD11a/18, CD54(ICAM-1), CD106(VCAM), and CD49d/29(VLA-4).